BMS bids $4.5B for ImClone

They're partners on the cancer med Erbitux, so why not join forces completely? Bristol-Myers Squibb has offered $4.5 billion for ImClone Systems, a $60-per-share price that represents about a 40 percent premium over the past month's closing prices. Release | Report